title: AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.
abstract: Gene delivery to the primate central nervous system via recombinant adeno-associated viral vectors (AAV) allows neurophysiologists to control and observe neural activity precisely. A current limitation of this approach is variability in vector transduction efficiency. Low levels of transduction can foil experimental manipulations, prompting vector readministration. The ability to make multiple vector injections into the same animal, even in cases where successful vector transduction has already been achieved, is also desirable. However, vector readministration has consequences for humoral immunity and gene delivery that depend on vector dosage and route of administration in complex ways. As part of optogenetic experiments in rhesus monkeys, we analyzed blood sera collected before and after AAV injections into the brain and quantified neutralizing antibodies to AAV using an in vitro assay. We found that injections of AAV1 and AAV9 vectors elevated neutralizing antibody titers consistently. These immune responses were specific to the serotype injected and were long lasting. These results demonstrate that optogenetic manipulations in monkeys trigger immune responses to AAV capsids, suggesting that vector readministration may have a higher likelihood of success by avoiding serotypes injected previously.NEW & NOTEWORTHYAdeno-associated viral vector (AAV)-mediated gene delivery is a valuable tool for neurophysiology, but variability in transduction efficiency remains a bottleneck for experimental success. Repeated vector injections can help overcome this limitation but affect humoral immune state and transgene expression in ways that are poorly understood. We show that AAV vector injections into the primate central nervous system trigger long-lasting and serotype-specific immune responses, raising the possibility that switching serotypes may promote successful vector readministration.
authors.affiliation: Department of Physiology and Biophysics, Washington National Primate Research Center, University of Washington, Seattle, Washington.
authors.forename: Skyler D
authors.initials: SD
authors.lastname: Mendoza
authors.affiliation: Department of Physiology and Biophysics, Washington National Primate Research Center, University of Washington, Seattle, Washington.
authors.forename: Yasmine
authors.initials: Y
authors.lastname: El-Shamayleh
authors.affiliation: Department of Physiology and Biophysics, Washington National Primate Research Center, University of Washington, Seattle, Washington ghorwitz@u.washington.edu.
authors.forename: Gregory D
authors.identifier: 0000-0001-5130-5259
authors.initials: GD
authors.lastname: Horwitz
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D001921:Brain / Q000378:metabolism*; D000229:Dependovirus / Q000235:genetics* / Q000276:immunology; D005260:Female; D018014:Gene Transfer Techniques / Q000009:adverse effects*; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D057809:HEK293 Cells; D006801:Humans; D056724:Immunity, Humoral; D008253:Macaca mulatta; D008297:Male; D062308:Optogenetics / Q000009:adverse effects* / Q000379:methods
chemical_list: D057134:Antibodies, Neutralizing
keywords: AAV vectors; neutralizing antibodies; nonhuman primate; optogenetics